CID16020046

产品编号: DC10873 Featured
CID16020046
结构式
834903-43-4
此产品仅供科研所需,我们不出售给病人
​我们将匹配市场上最好的价格给您
Email:order@dcbio.cn
免费咨询电话:4008862077
我们的合作伙伴:
  • 20
  • 19
  • 18
  • 17
  • 16
  • 15
  • 14
  • 12
  • 11
  • 10
  • 9
  • 8
  • 13
  • 6
  • 5
  • 4
  • 3
  • 2
  • 1
中国地区超过5000个高品质化合物库存
应用领域
CID 16020046是GPR55(LPI 受体) 选择性抑制剂, IC50为150nM。
Cas No.: 834903-43-4
名称: 4-[4,6-Dihydro-4-(3-hydroxyphenyl)-3-(4-methylphenyl)-6-oxopyrrolo[3,4-c]pyrazol-5(1H)-yl]benzoic acid
别名: CID16020046,CID 16020046,CID 16020046
SMILES: O=C1N(C5=CC=C(C(O)=O)C=C5)C(C4=CC=CC(O)=C4)C2=C1NN=C2C3=CC=C(C)C=C3
分子式: C25H19N3O4
分子量: 425.44
纯度:
保存条件: 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Description:
In Vivo:
In Vitro:
References: CID 16020046 is a potent and selective GPR55(LPI receptor) antagonist; inhibitsGPR55 constitutive activity with IC50 of 0.15 uM. IC50 value: 0.15 uM [1] Target: GPR55 antagonist In yeast cells expressing human GPR55, CID16020046 antagonized agonist-induced receptor activation. In human embryonic kidney(HEK293) cells stably expressing human GPR55, the compound behaved as an antagonist on LPI-mediated Ca2+ release and extracellular signal-regulated kinases activation, but not in HEK293 cells expressing cannabinoid receptor 1 or 2.CID16020046 concentration dependently inhibited LPI-induced activation of nuclear factor of activated T-cells (NFAT), nuclear factor k of activated B cells (NF-kB) and serum response element, translocation of NFAT and NF-kB, and GPR55 internalization. It reduced LPI-induced wound healing in primary human lung microvascular endothelial cells and reversed LPI-inhibited platelet aggregation.
Kinase Assay:
Cell Assay:
Animal Administration:
References:
MSDS
TITLE DOWNLOAD
MSDS_614_DC10873_834903-43-4
COA
LOT NO. DOWNLOAD
产品编号 产品名称 应用领域
DC10873 CID16020046 CID 16020046是GPR55(LPI 受体) 选择性抑制剂, IC50为150nM。